

RÉFÉRENCES

- 1. te Velthuis AJW, van den Worm SHE, Sims AC, Baric RS, Snijder EJ, van Hemert MJ.** Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog.* 2010;6: e1001176–e1001176. doi:10.1371/journal.ppat.1001176
- 2. Prasad AS, Fitzgerald JT, Bao B, Beck FWJ, Chandrasekar PH.** Duration of Symptoms and Plasma Cytokine Levels in Patients with the Common Cold Treated with Zinc Acetate. *Ann Intern Med.* 2000;133: 245–252. doi:10.7326/0003-4819-133-4-200008150-00006
- 3. Suara RO, Crowe Jr JE.** Effect of zinc salts on respiratory syncytial virus replication. *Antimicrob Agents Chemother.* 2004;48: 783–790. doi:10.1128/aac.48.3.783-790.2004
- 4. Singh M, Das RR.** Zinc for the common cold. *Cochrane Database Syst Rev.* 2015;2015. doi:10.1002/14651858.CD001364.pub5
- 5. Carlucci PM, Ahuja T, Petrilli C, Rajagopalan H, Jones S, Rahimian J.** Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. medRxiv. 2020; 2020.05.02.20080036. doi:10.1101/2020.05.02.20080036
- 6. Vogel-González M, Talló-Parra M, Herrera-Fernández V, Pérez-Vilaró G, Chillón M, Nogués X, et al.** Low zinc levels at clinical admission associates with poor outcomes in COVID-19. medRxiv. 2020; 2020.10.07.20208645. doi:10.1101/2020.10.07.20208645
- 7. Finzi E.** Treatment of SARS-CoV-2 with high dose oral zinc salts: A report on four patients. *Int J Infect Dis.* 2020;99: 307–309. doi:https://doi.org/10.1016/j.ijid.2020.06.006
- 8. Derwand R, Scholz M, Zelenko V.** COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. *Int J Antimicrob Agents.* 2020;56: 106214. doi:10.1016/j.ijantimicag.2020.106214
- 9. Dubourg G, Lagier JC, Brouqui P, Casalta JP, Jacomo V, La Scola B, et al.** Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? *J Microbiol Immunol Infect.* 2021. doi:10.1016/j.jmii.2021.01.012
- 10. Jothimani D, Kailasam E, Danielraj S, Nallathambi B, Ramachandran H, Sekar P, et al.** COVID-19: Poor outcomes in patients with zinc deficiency. *Int J Infect Dis.* 2020;100: 343–349. doi:10.1016/j.ijid.2020.09.014
- 11. Rahman MT, Idid SZ.** Can Zn Be a Critical Element in COVID-19 Treatment? *Biol Trace Elem Res.* 2021;199: 550–558. doi:10.1007/s12011-020-02194-9
- 12. Ferder L, Giménez VMM, Inserra F, Tajer C, Antonietti L, Mariani J, et al.** Vitamin D supplementation as a rational pharmacological approach in the COVID-19 pandemic. *Am J Physiol - Lung Cell Mol Physiol.* 2020;319: L941-L948. doi:10.1152/AJPLUNG.00186.2020
- 13. Charoengam N, Holick MF.** Immunologic effects of vitamin d on human health and disease. *Nutrients.* 2020;12: 2097. doi:10.3390/nu12072097
- 14. Jolliffe DA, Camargo CA, Sluyter JD, Aglipay M, Aloia JF, Bergman P, et al.** Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials. medRxiv. 2020; 2020.07.14.20152728. doi:10.1101/2020.07.14.20152728
- 15. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al.** Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ.* 2017;356: i6583. doi:10.1136/bmj.i6583
- 16. Bergman P, Lindh ÅU, Björkhem-Bergman L, Lindh JD.** Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *PLoS One.* 2013;8: e65835. Available: <https://doi.org/10.1371/journal.pone.0065835>

- 17. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H.** Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. *Am J Clin Nutr.* 2010;91: 1255– 1260. doi:10.3945/ajcn.2009.29094
- 18. Yadav D, Birdi A, Tomo S, Charan J, Bhardwaj P, Sharma P.** Association of Vitamin D Status with COVID19 Infection and Mortality in the Asia Pacific region: A Cross-Sectional Study. *Indian J Clin Biochem.* 2021. doi:10.1007/s12291-020-00950-1
- 19. Bakaloudi DR, Chourdakis M.** Is vitamin D deficiency associated with the COVID-19 epidemic in Europe? medRxiv. 2021; 2021.01.28.21250673. doi:10.1101/2021.01.28.21250673
- 20. Walrand S.** Autumn COVID-19 surge dates in Europe correlated to latitudes, not to temperaturehumidity, pointing to vitamin D as contributing factor. *Sci Rep.* 2021;11: 1981. doi:10.1038/s41598-021-81419-w
- 21. Demir M, Demir F, Aygun H.** Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease. *J Med Virol.* 2021;93: 2992–2999. doi: <https://doi.org/10.1002/jmv.26832>
- 22. Israel A, Cicurel A, Feldhamer I, Dror Y, Giveon SM, Gillis D, et al.** The link between vitamin D deficiency and Covid-19 in a large population. medRxiv. 2020; 2020.09.04.20188268. doi:10.1101/2020.09.04.20188268
- 23. Brenner H, Holleczeck B, Schöttker B.** Vitamin D insufficiency and deficiency and mortality from respiratory diseases in a cohort of older adults: Potential for limiting the death toll during and beyond the COVID-19 pandemic? *Nutrients.* 2020;12: 2488. doi:10.3390/nu12082488
- 24. Ahmed F.** A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection. *Front Immunol.* 2020;11: 590459. doi:10.3389/fimmu.2020.590459
- 25. Griffin G, Hewison M, Hopkin J, Kenny R, Quinton R, Rhodes J, et al.** Vitamin D and COVID-19: Evidence and recommendations for supplementation. *R Soc Open Sci.* 2020;7: 201912. doi:10.1098/rsos.201912rsos201912
- 26. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al.** Evidence that vitamin d supplementation could reduce risk of influenza and covid-19 infections and deaths. *Nutrients.* 2020;12: 988. doi:10.3390/nu12040988
- 27. Ali N.** Role of vitamin D in preventing of COVID-19 infection, progression and severity. *J Infect Public Health.* 2020;13: 1373–1380. doi:10.1016/j.jiph.2020.06.021
- 28. Miri M, Kouчек M, Rahat Dahmardeh A, Sistanizad M.** Effect of High-Dose Vitamin D on Duration of Mechanical Ventilation in ICU Patients. *Iran J Pharm Res IJPR.* 2019;18: 1067–1072. doi:10.22037/ijpr.2019.1100647
- 29. Rastogi A, Bhansali A, Khare N, Suri V, Yaddanapudi N, Sachdeva N, et al.** Short term, high-dose vitamin D supplementation for COVID-19 disease: a randomised, placebo-controlled, study (SHADE study). *Postgrad Med J.* 2020; postgradmedj-2020-139065. doi:10.1136/postgradmedj-2020-139065
- 30. Entrenas Castillo M, Entrenas Costa LM, Vaquero Barrios JM, Alcalá Díaz JF, López Miranda J, Bouillon R, et al.** “Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study.” *J Steroid Biochem Mol Biol.* 2020;203: 105751. doi: <https://doi.org/10.1016/j.jsbmb.2020.105751>
- 31. Nogués X, Ovejero Crespo D, Quesada Gómez J, Bouillon R, Arenas D, Pascual J, et al.** Calcifediol Treatment and COVID-19-Related Outcomes. *SSRN Electron J.* 2021. doi:10.2139/ssrn.3771318
- 32. Annweiler C, Hanotte B, Grandin de l’Eprevier C, Sabatier J-M, Lafaie L, Célarier T.** Vitamin D and survival in COVID-19 patients: A quasi-experimental study. *J Steroid Biochem Mol Biol.* 2020;204: 105771. doi: <https://doi.org/10.1016/j.jsbmb.2020.105771>
- 33. Ling SF, Broad E, Murphy R, Pappachan JM, Pardesi-Newton S, Kong M-F, et al.** High-Dose Cholecalciferol Booster Therapy is Associated with a Reduced Risk of Mortality in Patients with COVID19: A Cross-Sectional Multi-Centre Observational Study. *Nutrients.* 2020. p. 3799. doi:10.3390/nu12123799

- 34. Cangiano B, Fatti LM, Danesi L, Gazzano G, Croci M, Vitale G, et al.** Mortality in an Italian nursing home during COVID-19 pandemic: correlation with gender, age, ADL, vitamin D supplementation, and limitations of the diagnostic tests. *Aging (Albany NY)*. 2020;12: 24522–24534. doi:10.18632/aging.202307
- 35. Alcalá-díaz JF, Limia-perez L, Gomez-huelgas R, Martín-escalante MD, Cortes-rodriguez B, Zambranagarcia JL, et al.** Calcifediol Treatment and Hospital Mortality Due to COVID-19 : A Cohort Study. 2021;3: 1–13.
- 36. Loucera C, Peña-Chilet M, Esteban-Medina M, Muñozerro-Muñiz D, Villegas R, Lopez-Miranda J, et al.** Real world evidence of calcifediol use and mortality rate of COVID-19 hospitalized in a large cohort of 16,401 Andalusian patients. *medRxiv*. 2021; 2021.04.27.21255937. doi:10.1101/2021.04.27.21255937
- 37. Lehrer S, Rheinstein PH.** Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2. *In Vivo (Brooklyn)*. 2020;34: 3023–3026. doi:10.21873/invivo.12134
- 38. Cally L, Druce JD, Catton MG, Jans DA, Wagstaff KM.** The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res*. 2020;178: 104787. doi:10.1016/j.antiviral.2020.104787
- 39. Sen Gupta PS, Biswal S, Panda SK, Ray AK, Rana MK.** Binding mechanism and structural insights into the identified protein target of COVID-19 and importin- α with in-vitro effective drug ivermectin. *J Biomol Struct Dyn*. 2020;0: 1–10. doi:10.1080/07391102.2020.1839564
- 40. Swargiary A.** Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies. *Res Sq*. 2020. Available: <https://doi.org/10.21203/rs.3.rs-73308/v1>
- 41. Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al.** The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β 1 heterodimer. *Antiviral Res*. 2020;177. doi:10.1016/j.antiviral.2020.104760
- 42. Zhang X, Song Y, Ci X, An N, Ju Y, Li H, et al.** Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. *Inflamm Res*. 2008;57: 524–529. doi:10.1007/s00011-008-8007-8 43. Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N, et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. *Fundam Clin Pharmacol*. 2009;23: 449–455. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19453757
- 44. Zhang X, Song Y, Xiong H, Ci X, Li H, Yu L, et al.** Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages. *Int Immunopharmacol*. 2009;9: 354–359. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19168156
- 45. Bernigaud C, Guillemot D, Ahmed-Belkacem A, Grimaldi-Bensouda L, Lespine A, Berry F, et al.** Oral ivermectin for a scabies outbreak in a long-term-care facility: Potential value in preventing COVID-19 and associated mortality? *Br J Dermatol*. 2021;184: 1207–1209. doi:10.1111/bjd.19821
- 46. Elgazzar A, Hany B, Youssef SA.** Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. *Res Sq*. 2020;PREPRINT: 1–9. Available: <https://doi.org/10.21203/rs.3.rs100956/v3>
- 47. Hellwig MD, Maia A.** A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin. *Int J Antimicrob Agents*. 2021;57: 106248. doi:10.1016/j.ijantimicag.2020.106248
- 48. Carvallo HE, Hirsch RR, Psaltis A, Contrera V.** Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel. *J Biomed Res Clin Investig*. 2020;2: 1–6.
- 49. Shouman W, Hegazy A, Nafae R, Sileem A.** Use of Ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt : A Randomised clinical trial. *J Clin Diagnostic Res*. 2021;15: 27–32. doi:10.7860/JCDR/2021/46795.14529
- 50. Behera P, Patro BK, Singh AK, Chandanshive PD, Ravi Kumar SR, Pradhan SK, et al.** Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study. *PLoS One*. 2021;16: e0247163. doi:10.1101/2020.10.29.20222661

- 51. Carvallo HE, Hirsch RR, Farinella ME.** Safety and efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. medRxiv. 2020. doi:10.1101/2020.09.10.20191619
- 52. Gorial FI, Mashhadani S, Sayaly HM, Dakhil BD, AlMashhadani MM, Aljabory AM, et al.** Effectiveness of ivermectin as add-on therapy in COVID-19 management (pilot trial). medRxiv. 2020;2: 2–13. doi:10.1101/2020.07.07.20145979
- 53. Khan, M.S.I., Khan MSI, Debnath CR, Nath PN, Mahtab MA, Nabeka H, et al.** Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19. Arch Bronconeumol. 2020;56: 816–830.
- 54. Morgenstern J, Redondo JN, de León A, Canela JM, Torres N, Tavares J, et al.** The use of compassionate ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1. J Clin Trials. 2020;11: 9–12. doi:10.1101/2020.10.29.20222505
- 55. Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC.** A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. J Bangladesh Coll Physicians Surg. 2020;38: 10–15. doi:10.3329/jbcps.v38i0.47512
- 56. Rajter JC, Sherman MS, Fattah N, Vogel F, Sacks J, Rajter JJ.** Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest. 2021;159: 85–92. doi:10.1016/j.chest.2020.10.009
- 57. Patel AN, Mba SSD, Grainger DW.** Usefulness of Ivermectin in COVID-19 Illness. https://kitasatoinfection-control.info/swfu/d/COVID-19_illness.pdf. 2020; 1–13. Available: <https://ssrn.com/abstract=3580524>
- 58. Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulmir AS.** Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq. medRxiv. 2020;48. doi:<https://doi.org/10.1101/2020.10.26.20219345>
- 59. Niaee MS, Gheibi N, Namdar P, Allami A, Zolghadr L, Javadi A, et al.** Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial (preprint). Res Sq. 2020; 1–18. Available: <https://doi.org/10.21203/rs.3.rs-109670/v1>
- 60. Spoorthi V, Sasank S.** Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2. Int Arch Integr Med. 2020;7: 177–182. Available: <https://pesquisa.bvsalud.org/portal/resource/en/mdl-146744358>
- 61. Chamie J.** Real-World Evidence : The Case of Peru Causality between Ivermectin and COVID-19 Infection Fatality Rate. 2020.
- 62. Abdulmir AS, Ahmed S, Asghar A, Babalola OE, Basri R, Chachar AZK, et al.** Preliminary meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Res Sq. 2021.
- 63. Kory P.** Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19. Front Line COVID-19 Crit Care Alliance. 2021; 1–21.
- 64. Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, et al.** Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021;1: e1–e27. doi:doi: 10.1097/MJT.0000000000001402
- 65. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al.** Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6: 16. doi:10.1038/s41421-020-0156-0
- 66. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al.** Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30: 269–271. doi:10.1038/s41422-020-0282-0
- 67. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.** Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. doi:10.1016/j.ijantimicag.2020.105949

- 68. Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al.** In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. *Microb Pathog.* 2020;145: 104228. doi:<https://doi.org/10.1016/j.micpath.2020.104228>
- 69. Gautret P, Million M, Jarrot P-A, Camoin-Jau L, Colson P, Fenollar F, et al.** Natural history of COVID-19 and therapeutic options. *Expert Rev Clin Immunol.* 2020;16: 1159–1184. doi:10.1080/1744666X.2021.1847640
- 70. Gao J, Tian Z, Yang X.** Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends.* 2020;14: 72–73. doi:10.5582/bst.2020.01047
- 71. Roussel Y, Raoult D.** Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences. *New microbes new Infect.* 2020;38: 100710. doi:10.1016/j.nmni.2020.100710
- 72. Million M, Gautret P, Colson P, Roussel Y, Dubourg G, Chabriere E, et al.** Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. *New Microbes New Infect.* 2020;38: 100709. doi: <https://doi.org/10.1016/j.nmni.2020.100709>
- 73. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al.** Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv.* 2020; 2020.03.22.20040758. doi:10.1101/2020.03.22.20040758
- 74. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al.** Treating COVID-19 with Chloroquine. *J Mol Cell Biol.* 2020;12: 322–325. doi:10.1093/jmcb/mjaa014
- 75. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al.** Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ.* 2020;369: m1849. doi:10.1136/bmj.m1849
- 76. Chen L, Zhang Z-Y, Fu J-G, Feng Z-P, Zhang S-Z, Han Q-Y, et al.** Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. *medRxiv.* 2020; 2020.06.19.20136093. doi:10.1101/2020.06.19.20136093
- 77. Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, et al.** A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. *N Engl J Med.* 2020;384: 417–427. doi:10.1056/NEJMoa2021801
- 78. Guérin V, Lévy P, Thomas J-L, Lardenois T, Lacrosse P, Sarrazin E, et al.** Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19. *Asian J Med Heal.* 2020;18: 45–55. doi:10.9734/ajmah/2020/v18i730224
- 79. Hong KS, Jang JG, Hur J, Lee JH, Kim HN, Lee W, et al.** Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication. *Infect Chemother.* 2020;52: 396–402. Available: <https://doi.org/10.3947/ic.2020.52.3.396>
- 80. Bernabeu-Wittel M, Ternero-Vega JE, Nieto-Martín MD, Moreno-Gaviño L, Conde-Guzmán C, Delgado-Cuesta J, et al.** Effectiveness of a On-site Medicalization Program for Nursing Homes With COVID-19 Outbreaks. *Journals Gerontol Ser A.* 2021;76: e19–e27. doi:10.1093/gerona/glaa192
- 81. Ip A, Ahn J, Zhou Y, Goy AH, Hansen E, Pecora AL, et al.** Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. *BMC Infect Dis.* 2021;21: 72. doi:10.1186/s12879-021-05773-w
- 82. Su Y, Ling Y, Ma Y, Tao L, Miao Q, Shi Q, et al.** Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China. *Biosci Trends.* 2020. doi:10.5582/BST.2020.03340
- 83. Mokhtari M, Mohraz M, Gouya MM, Namdari Tabar H, Tabrizi J-S, Tayeri K, et al.** Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. *Int Immunopharmacol.* 2021;96: 107636. doi: <https://doi.org/10.1016/j.intimp.2021.107636>

- 84. Million M, LAGIER J-C, TISSOT-DUPONT H, PAROLA P, BROUQUI P, RAOULT D.** Early Treatment with Hydroxychloroquine and Azithromycin in 10,429 COVID-19 Outpatients: A Monocentric Retrospective Cohort Study. preprint. 2021;Mai. doi: <https://doi.org/10.35088/vadm-jx92>
- 85. Venditto VJ, Haydar D, Abdel-Latif A, Gensel JC, Anstead MI, Pitts MG, et al.** Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. *Front Immunol.* 2021;12: 1–19. doi:10.3389/fimmu.2021.574425
- 86. Pani A, Lauriola M, Romandini A, Scaglione F.** Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. *Int J Antimicrob Agents.* 2020;56: 106053. doi:10.1016/j.ijantimicag.2020.106053
- 87. Gielen V, Johnston SL, Edwards MR.** Azithromycin induces anti-viral responses in bronchial epithelial cells. *Eur Respir J.* 2010. doi:10.1183/09031936.00095809
- 88. Asada M, Yoshida M, Suzuki T, Hatachi Y, Sasaki T, Yasuda H, et al.** Macrolide antibiotics inhibit respiratory syncytial virus infection in human airway epithelial cells. *Antiviral Res.* 2009. doi:10.1016/j.antiviral.2009.05.003
- 89. Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C, et al.** Zika virus cell tropism in the developing human brain and inhibition by azithromycin. *Proc Natl Acad Sci U S A.* 2016. doi:10.1073/pnas.1618029113
- 90. Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A, et al.** Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. *J Antibiot (Tokyo).* 2019. doi:10.1038/s41429-019-0204-x
- 91. Zeng S, Meng X, Huang Q, Lei N, Zeng L, Jiang X, et al.** Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo. *Int J Antimicrob Agents.* 2019. doi:10.1016/j.ijantimicag.2018.12.009
- 92. Tahan F, Ozcan A, Koc N.** Clarithromycin in the treatment of RSV bronchiolitis: A double-blind, randomised, placebo-controlled trial. *Eur Respir J.* 2007. doi:10.1183/09031936.00029206 93. Arabi YM, Deeb AM, Al-Hameed F, Mandourah Y, Almekhlafi GA, Sindi AA, et al. Macrolides in critically ill patients with Middle East Respiratory Syndrome. *Int J Infect Dis.* 2019. doi:10.1016/j.ijid.2019.01.041
- 94. Lee N, Wong CK, Chan MCW, Yeung ESL, Tam WWS, Tsang OTY, et al.** Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial. *Antiviral Res.* 2017. doi:10.1016/j.antiviral.2017.05.008
- 95. Higashi F, Kubo H, Yasuda H, Nukiwa T, Yamaya M.** Additional treatment with clarithromycin reduces fever duration in patients with influenza. *Respir Investig.* 2014. doi:10.1016/j.resinv.2014.05.001
- 96. Kakeya H, Seki M, Izumikawa K, Kosai K, Morinaga Y, Kurihara S, et al.** Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: A multicenter, open-label, randomized study. *PLoS One.* 2014. doi:10.1371/journal.pone.0091293
- 97. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, et al.** Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. *Travel Med Infect Dis.* 2020. doi:10.1016/j.tmaid.2020.101738
- 98. Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A, et al.** Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. *Travel Med Infect Dis.* 2020;36. doi:10.1016/j.tmaid.2020.101791
- 99. Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarne D, Goldwirt L, et al.** No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. *Medecine et Maladies Infectieuses.* 2020. doi:10.1016/j.medmal.2020.03.006

- 100. Furtado RHM, Berwanger O, Fonseca HA, Corrêa TD, Ferraz LR, Lapa MG, et al.** Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. *Lancet*. 2020. doi:10.1016/S0140-6736(20)31862-6
- 101. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al.** Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. *N Engl J Med*. 2020. doi:10.1056/nejmoa2019014
- 102. Eljaaly K, Alshehri S, Aljabri A, Abraham I, Al Mohajer M, Kalil AC, et al.** Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis. *BMC Infect Dis*. 2017;17: 1–7. doi:10.1186/s12879-017-2495-5
- 103. Malek AE, Granwehr BP, Kontoyiannis DP.** Doxycycline as a potential partner of COVID-19 therapies. *IDCases*. 2020;21: e00864. doi:10.1016/j.idcr.2020.e00864
- 104. Kanth Manne B, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al.** Platelet gene expression and function in patients with COVID-19. *Blood*. 2020;136: 1317–1329. doi:10.1182/blood.2020007214
- 105. Tenenbaum A, Grossman E, Shemesh J, Fisman EZ, Nosrati I, Motro M.** Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. *Am J Hypertens*. 2000;13: 776–782. doi:10.1016/S0895-7061(00)00268-5
- 106. Osborne TF, Veigulis ZP, Arreola DM, Mahajan SM, Roosli E, Curtin CM.** Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. *PLoS One*. 2021;16: 5–14. doi:10.1371/journal.pone.0246825
- 107. Chow JH, Khanna AK, Kethireddy S, Yamane D, Levine A, Jackson AM, et al.** Aspirin Use Is Associated with Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients with Coronavirus Disease 2019. *Anesth Analg*. 2021;132: 930–941. doi:10.1213/ANE.0000000000005292
- 108. Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W, et al.** The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. *J Virol*. 2020;95: 1–14. doi:10.1128/jvi.01648-20
- 109. Ramakrishnan S, Nicolau D V, Langford B, Mahdi M, Jeffers H, Mwasuku C, et al.** Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. *Lancet Respir Med*. 2021;19: 1–10. doi:10.1016/s2213-2600(21)00160-0
- 110. Yu L-M, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al.** Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. *medRxiv*. 2021. doi:10.1101/2021.04.10.21254672
- 111. McCullough PA, Kelly RJ, Ruocco G, Lerma E, Tumlin J, Wheelan KR, et al.** Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. *Am J Med*. 2021;134: 16–22. doi:10.1016/j.amjmed.2020.07.003